Homepage
Healthcare · Biotechnology · United States · Updated May 10, 8:18pm
$7.28
Price
$72.8M
Market Cap
75
Employees
0.89
Beta
Robert Etherington
CEO
Business Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-2.75
Stock Price: $7.28
EPS (Diluted): -2.65
EPS (Diluted): -2.65
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-3.29
Stock Price: $7.28
Total Equity: -$17.59M
Shares: 9,858,907
Total Equity: -$17.59M
Shares: 9,858,907
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-3.44
Market Cap: $72.80M
Total Debt: $18.42M
Cash: $5.19M
EBITDA: -$21.59M
Total Debt: $18.42M
Cash: $5.19M
EBITDA: -$21.59M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$74.4M
Market Cap: $72.80M
Total Debt: $18.42M
Cash: $5.19M
Total Debt: $18.42M
Cash: $5.19M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
78.5%
Gross Profit: $157,000
Revenue: $200,000
Revenue: $200,000
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-11,541.5%
Operating Income: -$23.08M
Revenue: $200,000
Revenue: $200,000
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-13,086.5%
Net Income: -$26.17M
Revenue: $200,000
Revenue: $200,000
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
148.8%
Net Income: -$26.17M
Total Equity: -$17.59M
Total Equity: -$17.59M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
529.7%
Operating Income: -$23.08M
Tax Rate: 0.0%
Equity: -$17.59M
Total Debt: $18.42M
Cash: $5.19M
Tax Rate: 0.0%
Equity: -$17.59M
Total Debt: $18.42M
Cash: $5.19M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.83
Current Assets: $8.98M
Current Liabilities: $10.78M
Current Liabilities: $10.78M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-1.05
Short-Term Debt: $4.88M
Long-Term Debt: $13.54M
Total Debt: $18.42M
Total Equity: -$17.59M
Long-Term Debt: $13.54M
Total Debt: $18.42M
Total Equity: -$17.59M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.02
Revenue: $200,000
Shares: 9,858,907
Shares: 9,858,907
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-1.78
Total Equity: -$17.59M
Shares: 9,858,907
Shares: 9,858,907
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.89
Operating CF: -$18.55M
CapEx: -$39,000
Shares: 9,858,907
CapEx: -$39,000
Shares: 9,858,907
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $7.28
Stock Price: $7.28
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$26.17M
Net Income: -$26.17M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CLNN against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $723,000 | $473,000 | $654,000 | $342,000 | $200,000 |
| Cost of Revenue | $289,000 | $26,000 | $121,000 | $70,000 | $43,000 |
| Gross Profit | $434,000 | $447,000 | $533,000 | $272,000 | $157,000 |
| Operating Expenses | $50.4M | $48.9M | $41.1M | $33.4M | $23.2M |
| Operating Income | -$50.0M | -$48.4M | -$40.5M | -$33.1M | -$23.1M |
| Net Income | -$9.7M | -$29.9M | -$49.5M | -$39.4M | -$26.2M |
| EBITDA | -$8.3M | -$25.6M | -$43.2M | -$33.7M | -$21.6M |
| EPS | $-3.16 | $-4.69 | $-9.43 | $-5.67 | $-2.65 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $50.3M | $18.3M | $28.8M | $12.2M | $5.2M |
| Total Current Assets | $54.6M | $29.2M | $38.9M | $16.2M | $9.0M |
| Total Assets | $63.1M | $44.5M | $52.3M | $27.3M | $18.1M |
| Current Liabilities | $6.0M | $13.9M | $25.3M | $10.3M | $10.8M |
| Long-Term Debt | $19.1M | $19.3M | $7.2M | $15.4M | $13.5M |
| Total Liabilities | $50.5M | $41.3M | $39.0M | $36.2M | $35.7M |
| Total Equity | $12.6M | $3.2M | $13.4M | -$8.9M | -$17.6M |
| Retained Earnings | -$163.3M | -$193.2M | -$242.7M | -$282.1M | -$308.3M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$34.6M | -$39.0M | -$30.2M | -$21.3M | -$18.5M |
| Capital Expenditure | -$1.3M | -$5.2M | $-330,000 | $-15,000 | $-39,000 |
| Free Cash Flow | -$36.0M | -$44.2M | -$30.5M | -$21.3M | -$18.6M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$8.9M | -$32.0M | $10.5M | -$16.7M | -$7.0M |
Analyst Estimates (Annual)
| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$37.7M $1.7M – $73.7M
|
$165.8M $14.0M – $317.6M
|
$300.2M $25.3M – $575.0M
|
$457.7M $38.5M – $876.8M
|
| EBITDA |
-$37.7M -$73.7M – -$1.7M
|
-$165.8M -$317.6M – -$14.0M
|
-$300.2M -$575.0M – -$25.3M
|
-$457.7M -$876.8M – -$38.5M
|
| Net Income |
-$12.6M -$16.1M – -$9.1M
|
$45.3M -$8.6M – $74.1M
|
$54.8M -$10.4M – $120.0M
|
$86.3M -$16.4M – $189.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -34.6% | +38.3% | -47.7% | -41.5% |
| Gross Profit Growth | +3.0% | +19.2% | -49.0% | -42.3% |
| Operating Income Growth | +3.1% | +16.3% | +18.4% | +30.2% |
| Net Income Growth | -207.2% | -65.5% | +20.4% | +33.6% |
| EBITDA Growth | -206.9% | -68.9% | +22.1% | +35.9% |
No community reviews yet for CLNN.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27